Active Ingredient(s): Telotristat Ethyl
FDA Approved: * February 28, 2017
Category: Gastrointestinal

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Xermelo Overview

Telotristat ethyl (USAN, brand name Xermelo) is a prodrug of telotristat, which is an inhibitor of tryptophan hydroxylase. It is formulated as telotristat etiprate — a hippurate salt of telotristat ethyl.[1] On February 28, 2017, the U.S. Food and Drug Administration (FDA) approved telotristat ethyl in combination with somatostatin analog (SSA) therapy for the treatment of adults with diarrhea associated with carcinoid syndrome that SSA therapy alone has inadequately con...

Read more Xermelo Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Telotristat_ethyl

Recent Xermelo Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Telotristat Ethyl
  • Tablet: 250mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Xermelo: (2 results)

Sorted by National Drug Code
  • 70183-125 Xermelo 250 mg Oral Tablet by Lexicon Pharmaceuticals, Inc.
  • 70720-125 Xermelo 250 mg Oral Tablet by Tersera Therapeutics LLC

Other drugs which contain Telotristat Ethyl or a similar ingredient: (1 result)